Navigation Links
ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia
Date:1/31/2011

LOS ANGELES, Jan. 31, 2011 /PRNewswire/ -- ImaginAb, Inc. and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system. Leveraging Eurogentec's expertise in cGMP manufacturing of recombinant proteins, the collaboration will accelerate the development of ImaginAb's rich pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.

"With our rapidly expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase our capacity for fast, reliable protein production," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Eurogentec's Pichia technology has the potential to enable us to take a fresh look at how we do extremely rapid and cost-effective translation into humans with our antibody fragment technology."

Dr. Philippe Cronet, CSO of Eurogentec commented, "We are very committed to exploring new manufacturing strategies for ImaginAb's unique products. Our technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb".

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

About Eurogentec

Eurogentec is a cGMP accredited Contract Manufacturing Organization (CMO) offering process development and cGMP manufacturing services since 1994. Eurogentec manufactures recombinant proteins, plasmids, vaccines and conjugates in compliance with EU 2003/94/EC and US FDA 21CFR 210 and operates a full-service, state-of-the-art cGMP facility located in Belgium. In 2010, Eurogentec became part of Kaneka Corporation, Osaka, Japan. For more information about Eurogentec, visit www.eurogentec.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.; Eurogentec S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
2. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
5. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
11. febit and TGen Collaborate to Study New DNA Capture Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 6.35% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... Atlanta, GA (PRWEB) , ... April 25, 2017 , ... ... to their neck and back pain with a reputable physician in their area, announces ... The CRM protects patient information for patients who are looking for reputable physicians to ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, ... development and joint health in horses at the immunologic level. , The scientifically-developed ...
Breaking Medicine News(10 mins):